Famous Patents
The first commercial microwave oven was nearly 6 feet tall and weighed in at 750 pounds.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128719 | STREPTOCOCCUS VACCINE COMPOSITIONS AND METHODS OF USING THE SAME The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or ... | 05/24/2012 |
| 20120052088 | PNEUMOCOCCAL VACCINE AND USES THEREOF The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumococcal infections using said novel pneumococcal vaccines.... | 03/01/2012 |
| 20120034266 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSE BY A NUTRACEUTICAL ANTIOXIDANT The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention i... | 02/09/2012 |
| 20120034230 | Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE BACTERIA The invention provides protective antigens which are useful in vaccine compositions to induce protection against gram positive bacteria, particularly against S. agalactiae, S. pyogenes, S. pneumoniae, S. aureus, S. suis, and S. equi. ... | 02/09/2012 |
| 20120021003 | VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS BACTERIA OF VARIOUS SEROTYPES The present invention pertains to the use of Streptococcus suis antigens corresponding to Streptococcus suis bacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of... | 01/26/2012 |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20110311577 | METHOD OF PRODUCING A VACCINE The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatograp... | 12/22/2011 |
| 20110305688 | NEW VIRULENCE FACTORS OF STREPTOCOCCUS PNEUMONIAE The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also ant... | 12/15/2011 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110268763 | POLYNUCLEOTIDES THAT STIMULATE NEUTROPHILS The polynucleotides of the present invention are complementary to the Initiation Sites of microbes. Invading organisms, sensing the pH and nutrient deprivation of a physiologic environment quickly release these nucleotides triggering rapid growth and mutation—attribut... | 11/03/2011 |
| 20110250221 | Group A Streptococcus Pharmaceutical Compositions and Methods Thereof Isolated proteins and immunogenic fragments thereof, for use in the treatment and prevention of a Group A Streptococcus infection are provided. In particular, the invention provides pharmaceutical compositions and methods of prophylactic and/or therapeutic treatm... | 10/13/2011 |
| 20110243976 | COMPOSITIONS COMPRISING PNEUMOCOCCAL ANTIGENS Disclosed herein are various combinations of pneumococcal polypeptides for use in immunisation. Also disclosed herein are pneumococcal polypeptides that may be useful as single antigens. These polypeptides may optionally be used in combination with pneumococcal sacchari... | 10/06/2011 |
| 20110217329 | Vaccine The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with... | 09/08/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110171224 | PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION Disclosed are pharmaceutical compositions that include a PsrP polypeptide, a nucleic acid encoding a PsrP polypeptide, or an antibody or fragment thereof that binds to a PsrP polypeptide domain, and methods of inhibiting, modulating, treating, or preventing a bacterial ... | 07/14/2011 |
| 20110171252 | Streptococcus suis vaccines and diagnostic tests Described are Streptococcus suis infections in pigs, vaccines directed against those infections and tests for diagnosing S. suis infections. Provided is an isolated or recombinant nucleic acid encoding a capsular gene cluster of S. suis or a gene or... | 07/14/2011 |
| 20110171263 | COMPOSITIONS AND METHODS OF USE OF ORF-1358 FROM BETA-HEMOLYTIC STREPTOCOCCAL STRAINS The present invention relates to polynucleotides encoding Streptococcus group C and G polypeptides and their use in immunogenic compositions. The invention also relates to immunogenic compositions comprising polypeptides encoded by those polynucleotides. In addit... | 07/14/2011 |
| 20110159030 | MUCOSAL COMBINATION VACCINES FOR BACTERIAL MENINGITIS A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen ... | 06/30/2011 |
| 20110159040 | NOVEL IMMUNOGENS AND METHODS FOR DISCOVERY AND SCREENING THEREOF An aspect of the present invention provides for methods for identifying novel immunogens that when administered as vaccines elicit a cellular or humoral immunogenic response. In a particular embodiment, a method identified pneumococcal T-cell immunogens that elicit syst... | 06/30/2011 |
| 20110150931 | RAPID RESPONSES TO DELAYED BOOSTER IMMUNISATIONS Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ≦7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune re... | 06/23/2011 |
| 20110135679 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) at least first and second adjuvants, wherein the first adjuvant comprises microparticles and wherein the second adjuvant comprises an imidazoquinoline compound, and (c) a... | 06/09/2011 |
| 20110129501 | VACCINE COMPRISING RECOMBINANT CLPP PROTEIN OF STREPTOCOCCUS PNEUMONIAE A method for immunizing a human or animal against pneumococcal infections, comprising by administering a vaccine comprising a purified recombinant caseinolytic protease P (ClpP) protein of S. pneumoniae in an immunologically effective amount to the human or anima... | 06/02/2011 |
| 20110110979 | METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.... | 05/12/2011 |
| 20110111017 | USE OF IMMUNOGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOGEN INFECTIONS The invention provides compositions featuring cationic liposome nucleic acid molecules complexed with pathogen derived antigen and methods of using such compositions for the treatment or prevention of an infectious disease. Other features and advantages of the invention... | 05/12/2011 |
| 20110110982 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence... | 05/12/2011 |
| 20110104207 | GYRASE INHIBITORS AND USES THEREOF The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention al... | 05/05/2011 |
| 20110097360 | STREPTOCOCCUS PNEUMONIAE PILUS ANTIGENS Polypeptides from Streptococcus pneumoniae are described. In some aspects the polypeptides include pili polypeptides from a second pili island (pilus II island (INV1 04B)) identified in Streptococcus pneumoniae isolate INV1 04. In other aspects the polypep... | 04/28/2011 |
| 20110091506 | VACCINE COMPOSITIONS The present invention provides methods for the treatment or prevention of allergic airways diseases, the suppression of allergic immune responses, and the induction protective immunity against allergic airways diseases wherein the methods comprise administering to subje... | 04/21/2011 |
| 20110076306 | ARABINOGALACTAN FOR ENHANCING THE ADAPTIVE IMMUNE RESPONSE The present invention discloses a composition containing Arabinogalactan for enhancing the adaptive immune response in subjects to foreign antigen(s) by administering said composition prior, during and after the phase of exposure to said foreign antigen(s). Furthermore,... | 03/31/2011 |
| 20110064723 | Formulation for room temperature stabilization of a live attenuated bacterial vaccine This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are provided that stabilize the viability of live bacteria and live virus vacci... | 03/17/2011 |
| 20110038879 | IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES Compositions for preventing and/or treating S. pyogenes infection which comprise one or more active agents. The active agents are SLO antigens, nucleic acid molecules encoding the SLO antigens, and/or antibodies which selectively bind to the SLO antigens.... | 02/17/2011 |
| 20110033479 | PROTEINS EZRIN, SERPIN B5, PEROXIREDOXIN-2 AND HEAT SHOCK PROTEIN BETA-1 AS AUTOANTIGENS FOR PSORIASIS VULGARIS AND POSTSTREPTOCOCCAL DISEASES The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein β1, and/or peptides comprising at least 5 consecutive amino acid residues of one of these autoantigenic proteins having immunological activity, or fragment... | 02/10/2011 |
| 20110020403 | IMMUNIZING COMPOSITION The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of S. equi subsp. equi and subsp. zooep... | 01/27/2011 |
| 20110020395 | PROBIOTICS FOR USE IN EXPECTING FEMALE MAMMALS FOR ENHANCING THE IMMUNITY OF THEIR OFFSPRINGS The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of off-spring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure. Ultimately the use of probiotic in expec... | 01/27/2011 |
| 20110008419 | Vaccine Against Streptococcus Pneumoniae The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with... | 01/13/2011 |
| 20110002962 | Immunogenic PcpA Polypeptides and Uses Thereof Provided herein are compositions and methods for eliciting an immune response against Streptococcus pneumoniae. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PcpA and variants thereof, and nucleic acids... | 01/06/2011 |
| 20100303864 | CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES The invention relates to polynucleotides which are conserved or specific to one or more species of Streptococcus, Streptococcus species serotypes, and/or serotype isolates. In particular, the invention relates to polynucleotides from Streptococcus which ar... | 12/02/2010 |
| 20100297183 | IMMUNOGENIC STREPTOCOCCUS PROTEINS The invention provides means and methods for identifying a Streptococcus protein which is capable of eliciting an immune response against at least two Streptococcus strains and/or serotypes. The invention further discloses immunogenic compositions capable ... | 11/25/2010 |
| 20100297184 | Vaccines The invention provides Streptococcus vaccine strains (e.g. S. equi which is causative of ‘strangles’) comprising the following modifications in their genomes: (i) attenuation of one or more essential biosynthetic genes, (ii) attenuation of one or more ... | 11/25/2010 |
| 20100285135 | Nanoparticles For Use In Immunogenic Compositions Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such composi... | 11/11/2010 |
